Clinical analysis of the adverse reactions in 138 cases of multidrug-resistant tuberculosis following cycloserine treatment

doi:10.3969/j.issn.2095-3755.2018.03.010

Abstract

Abstract:

Objective To analyze the psychiatric and neurologic adverse reactions of cycloserine in 138 patients with multidrug-resistant tuberculosis. Methods Retrospective analysis was conducted based on the clinical data of 138 cases of multidrug-resistant tuberculosis who were admitted to the Department of Multidrug Resistant Tuberculosis, Hu’nan Chest Hospital from July 1, 2012 to June 30, 2014. The occurrence and treatment strategies of adverse reactions of cycloserine were summarized and analyzed. Results Of the 138 cases of multidrug-resistant tuberculosis using cycloserine, 18 (13.04%) occurred the psychiatric and neurologic adverse reactions. Seven (5.07%) cases discontinued cycloserine. They received 6Cm(Am)-Lfx(Mfx)-Pto-PAS-Z/18Lfx(Mfx)-Pto-PAS-Z regimen, and all psychiatric and neurologic adverse reactions disappeared. The remaining 11 (7.97%) cases increased the dosage of VitB6, and maintained the original regimen for anti-tuberculosis treatment. After treatment, they all did not occur the psychiatric and neurologic adverse reactions. Conclusion It is relatively safe to use cycloserine-containing regimen to treat multidrug-resistant tuberculosis, if we master the indications and closely monitor the adverse events.

Key words: Tuberculosis, pulmonary, Tuberculosis, multidrug-resistant, Cycloserine, Adverse reactions

Xin-min WEN,Kun-yun YANG,Heng-zhong YI,Dan-lin LUO,Yong ZHANG,Zhi-gang TANG,Juan LI,Tian YUAN. Clinical analysis of the adverse reactions in 138 cases of multidrug-resistant tuberculosis following cycloserine treatment[J]. Journal of Tuberculosis and Lung Health , 2018, 7(3): 194-197. doi: 10.3969/j.issn.2095-3755.2018.03.010

Figures/Tables 1

References 15

[1]	缪昌东, 姜继军 . 环丝氨酸致精神异常一例. 中国防痨杂志, 2013,35(6):480.
[2]	Behera C, Krishna K, Singh HR . Antitubercular drug-induced violent suicide of a hospitalised patient. BMJ Case Rep, 2014, 2014. pii: bcr2013201469. doi: 10.1136/bcr-2013-201469 URL pmid: 3902371
[3]	Sawant NS, Kate NS, Bhatankar SS , et al. Neuroleptic malignant syndrome in cycloserine-induced psychosis. Indian J Pharmacol, 2015,47(3):328-329. doi: 10.4103/0253-7613.157134 URL pmid: 26069374
[4]	Hwang TJ, Wares DF, Jafarov A , et al. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Int J Tuberc Lung Dis, 2013,17(10):1257-1266. doi: 10.5588/ijtld.12.0863 URL
[5]	王黎霞, 成诗明, 周林 . 结核菌/艾滋病病毒双重感染防治工作技术指导手册.北京: 人民卫生出版社, 2012.
[6]	宋艳华, 郭少晨, 高孟秋 , 等. 环丝氨酸治疗耐多药结核病的血药浓度及不良反应监测. 中国防痨杂志, 2014,36(5):399-401. doi: 10.3969/j.issn.1000-6621.2014.05.021 URL
[7]	Ramachandran G, Swaminathan S . Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf, 2015,38(3):253-269. doi: 10.1007/s40264-015-0267-y URL pmid: 25676682
[8]	程武, 谭守勇, 李艳 , 等. 环丝氨酸在治疗耐多药肺结核患者中的不良反应分析. 结核病与肺部健康杂志, 2015,4(4):247-249. doi: 10.3969/j.issn.2095-3755.2015.04.009 URL
[9]	Sharma B, Handa R, Nagpal K , et al. Cycloserine-induced psychosis in a young female with drug-resistant tuberculosis. Gen Hosp Psychiatry, 2014, 36(4): 451.e3-4. doi: 10.1016/j.genhosppsych.2014.03.009 URL pmid: 24766906
[10]	中国全球基金结核病项目办公室. 中国全球基金结核病项目实施细则:耐多药结核病防治领域. 北京:中国全球基金结核病项目办公室, 2012.
[11]	中国全球基金结核病项目办公室. 全国环丝氨酸使用培训班资料汇编. 北京:中国全球基金结核病项目办公室, 2013.
[12]	唐志冈, 易恒仲, 罗丹霖 , 等. 96例耐多药肺结核患者使用环丝氨酸导致神经、精神系统不良反应观察. 中国防痨杂志, 2015,37(2):203-205. doi: 10.3969/j.issn.1000-6621.2015.02.017 URL
[13]	肖和平 . 耐药结核病化学治疗指南(2010年).北京: 人民卫生出版社, 2011.
[14]	马丙乾 . 耐多药肺结核患者使用环丝氨酸的不良反应观察及处理. 中国防痨杂志, 2016,38(2):156-158. doi: 10.3969/j.issn.1000-6621.2016.02.017
[15]	李杨, 王飞, 吴琍敏 , 等. 环丝氨酸在耐多药结核病化学治疗中应用价值的探讨. 中国防痨杂志, 2018,40(2):168-172.

服药后时间 (月)	不良反应种类(例)								合计 (例)
服药后时间 (月)	头晕	焦虑	嗜睡	兴奋性增高	精神抑郁	烦躁不安	精神错乱	自杀倾向	合计 (例)
1	1	0	0	0	0	0	0	0	1
2	1	0	0	0	0	0	0	1	2
3	2	1	0	1	0	0	0	0	4
4	0	0	0	0	1	0	0	0	1
5	1	0	0	0	0	0	0	0	1
6	0	1	0	1	0	0	0	0	2
7	1	0	0	0	0	0	0	0	1
8	0	0	0	1	0	0	0	0	1
9	0	1	0	0	1	0	0	0	2
10	0	0	0	0	0	1	0	0	1
11	0	0	0	0	0	0	0	0	0
12	0	0	0	0	0	0	0	0	0
15	1	0	0	0	0	0	0	1	2
18	0	0	0	0	0	0	0	0	0
21	0	0	0	0	0	0	0	0	0
24	0	0	0	0	0	0	0	0	0
合计	7	3	0	3	2	1	0	2	18